We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04521569
Recruitment Status : Recruiting
First Posted : August 20, 2020
Last Update Posted : December 15, 2022
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Christine Lau, University of Maryland, Baltimore

Brief Summary:
The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

Condition or disease Intervention/treatment Phase
Lung Transplant Drug: Regadenoson Drug: Placebo Early Phase 1

Detailed Description:

Lung transplantation currently is one way to treat a variety of serious diseases and conditions such as emphysema, pulmonary fibrosis, and cystic fibrosis. Ischemia Reperfusion Injury (IRI) is a known problem that can happen during the first few days after a lung transplant. IRI can cause swelling of the lungs and low levels of oxygen. The most serious type of IRI can cause the transplanted lung to not work properly, it can even cause death. While new treatments and practices have been put into place to lower the chances of IRI, it is still a difficult problem to overcome after a lung transplant.

Molecule called Adenosine 2A receptor (A2AR) have been studied in animals with IRI for many years. Some of these studies suggest that with the use of A2AR agonist, the chance of IRI may be lowered or prevented. Regadenoson is a selective A2AR agonist.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomization to the EVLP with placebo or EVLP with Regadenoson groups will be performed in a 1:2 ratio.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: All study team members and subjects will be blinded to treatment assignment with the exception of the statisticians and investigational pharmacist preparing the study treatment.
Primary Purpose: Prevention
Official Title: A Randomized, Blinded, Multi-site, Pilot Study to Evaluate Adenosine 2A Receptor Agonist (REGADENOSON) in the Rehabilitation of Marginal Donor Lungs.
Actual Study Start Date : June 22, 2020
Estimated Primary Completion Date : July 22, 2023
Estimated Study Completion Date : August 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Regadenoson

Arm Intervention/treatment
Experimental: EVLP with Regadenoson
Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the study drug, Regadenoson.
Drug: Regadenoson
If the donor lungs are randomized the experimental arm, the administration of Regadenoson will be performed at each study site by a qualified medical professional. The donor lungs will be perfused with Regadenoson at a dosage of 1.44 microgram/kg/min (based on donor's weight) for a minimum of three hours and maximum of four hours, using a pediatric syringe pump into the EVLP circuit (XVIVO Perfusion System). The infusion will begin within 10 minutes of the start of the EVLP procedure. Once the EVLP is complete the lungs are re-flushed with Perfadex solution (removing the Steen™ solution and Regadenoson; standard for EVLP).
Other Name: Lexiscan

Placebo Comparator: EVLP with Steen solution
Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the same volume of Steen solution.
Drug: Placebo
If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
Other Name: Steen solution

Primary Outcome Measures :
  1. Lung Rehabilitation [ Time Frame: 30 days ]
    The primary endpoint is rehabilitation (yes, no) for marginal donor lungs that undergo ex-vivo perfusion using a "lung box" as assessed by the transplant surgeon and utilizing the "Toronto Method" clinical protocol. Rate of rehabilitation is defined as the proportion of sets of lungs that underwent EVLP with/without Regadenoson treatment and are determined to be eligible for implant.

Secondary Outcome Measures :
  1. Primary Lung Graft Dysfunction (PGD) Score [ Time Frame: 72 hours ]
    Primary graft dysfunction (PGD) is a clinical entity that reflects the development of early acute lung injury after lung transplantation. PGD severity is graded between 0 and 3 and it is measured at 6h, 12h, 24h, 48h and 72 hours after lung transplantation. A score of Score 0 means no PGD and 1-3 increasingly more severe. 3 is so severe requires ECMO support.

  2. Intensive care unit length of stay [ Time Frame: 8 weeks ]
    Participants will be followed for the duration of hospital stay, an expected average of 8 weeks

  3. Using of ECMO [ Time Frame: 1 week ]
    How often the patient will use ECMO due to lung infection after lung transplantation

  4. Duration on ventilator post-Operative [ Time Frame: 1 month ]
    Will measure how long the patient use ventilator post-operation.

  5. 12-month survival [ Time Frame: 12 months ]
    Patient survival 360 days after lung transplantation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Donor Lung Inclusion Criteria for EVLP

  1. At the time of clinical evaluation, the PaO2/FiO2 ≤ 300mm Hg OR
  2. If the PaO2/FiO2 is > 300mm hg and the donor has any one of more of the following donor risk factors:

    1. Multiple blood transfusions
    2. Pulmonary Edema detected via CXR, Bronchoscopy or palpation of the lungs
    3. Donation after cardiac death donors
    4. High risk donor history (example: asphyxia, hanging, drowning)

Donor lung Inclusion Criteria for Transplant Suitability after EVLP

  1. Delta PaO2 greater than 350 mmhg (measured with an FiO2 set at 1.0) at two consecutive time periods at 2, 3, or 4 hours of EVLP.
  2. Stability or improvement of other lung function parameters during EVLP perfusion, such as PVR, compliance, or airway pressures.
  3. Lungs clinically suitable for transplantation (e.g. without signs of significant contusions, edema, or secretion) in the opinion of the surgical investigator(s).

Participant Inclusion Criteria

  1. Subjects must be undergoing a single or bilateral lung transplantation for end-stage lung disease and thus meet all criteria to be listed. Single lungs are only allowable when initially placed as bilaterally block on EVLP circuit.
  2. Male or female subject, 18 -75 years of age.
  3. Subject agrees to accept EVLP perfused lungs.
  4. Subjects must sign a study specific informed consent prior to study entry.

Exclusion Criteria:

Donor Lung Exclusion Criteria for EVLP

  1. Donor lung has significant pneumonia as defined by positive bacterial growth in blood culture (not related to other source of infection) or persistent purulent, un-clearable secretions on bronchoscopy OR as determined by the investigator.
  2. Donor has aspirated gastric contents into the lung. Donor lung has significant mechanical lung injury or trauma.
  3. Donor lung has active infections disease, such as HIV, Hepatitis B or C, HTLV or syphilis.
  4. Donor lung must not be split and perfused as single lung on EVLP circuit.

Donor Lung Exclusion Criteria for Transplant Suitability after EVLP (All of the below must be negative)

  1. Delta PaO2 less than 350 mmHg (measured with FiO2 set at 1.0) at two consecutive time periods at 2, 3 or 4 hours of ex Vivo perfusion.
  2. > 10% functional deterioration of other lung parameters during EVLP such as PVR, compliance or airway pressures.

Participant Exclusion Criteria

  1. Subject requires preoperative extracorporeal membrane oxygenation (ECMO).
  2. Subjects who are receiving or have received within 30 days any other investigational agents.
  3. Subjects with Burkolderia cepacia.
  4. Subjects who have had a previous lung transplant.
  5. Subjects who have an uncontrolled concurrent illness including, but not limited to an ongoing or active infection, uncontrolled congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements per investigator discretion.
  6. Pregnant or breastfeeding women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04521569

Layout table for location contacts
Contact: Manal Al-Suqi, M.S.T.C 410-328-9409 MaAl-suqi@som.umaryland.edu
Contact: Emily Fleischmann 410-328-0943 EFleischmann@som.umaryland.edu

Layout table for location information
United States, Maryland
University of Maryland Medical Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Christine L Lau, MD, MBA    410-328-8407    cllau@som.umaryland.edu   
Contact: Manal Al-Suqi, MSTC    410-328-9409    MaAl-Suqi@som.umaryland.edu   
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195 |
Contact: Lindsey Piazza, RN    216-409-8492    PIAZZAL@ccf.org   
Principal Investigator: Kenneth McCurry, MD         
Sponsors and Collaborators
University of Maryland, Baltimore
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: Christine Lau, MD University of Maryland, Baltimore
Layout table for additonal information
Responsible Party: Christine Lau, Surgeon-in-Chief, Department of Surgery, University of Maryland, Baltimore
ClinicalTrials.gov Identifier: NCT04521569    
Other Study ID Numbers: UVA-LAU-02
5R01HL128492-04 ( U.S. NIH Grant/Contract )
First Posted: August 20, 2020    Key Record Dates
Last Update Posted: December 15, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Christine Lau, University of Maryland, Baltimore:
Lung Transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenosine A2 Receptor Agonists
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs